vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2021-18-3-375-384vestim-788Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEФакторы риска рецидива при аллогенной трансплантации у детей, подростков и молодых взрослых с острым лимфобластным лейкозомRelapse risk factors during allogeneic stem cell transplantation in children, adolescents and young adults with acute lymphoblastic leukemiahttps://orcid.org/0000-0002-7899-3773ПрудниковД. В.PrudnikauD. V.

Прудников Дмитрий Владимирович – врач-гематолог

ул. Фрунзенская, 43, 223053, д. Боровляны, Минский р-н

Dmitry V. Prudnikau – Hematologist

43, Frunzenskaya Str., 223053, v. Borovliany, Minsk region 

dima1911@mail.ruhttps://orcid.org/0000-0002-3193-4864КирсановаН. П.KirsanavaN. P.

Кирсанова Наталья Павловна – канд. мед. наук, врач-гематолог

ул. Фрунзенская, 43, 223053, д. Боровляны, Минский р-н

Natalia P. Kirsanava – Ph. D. (Med.), Hematologist

43, Frunzenskaya Str., 223053, v. Borovliany, Minsk region 

litvinko_natasha@mail.ruhttps://orcid.org/0000-0003-4172-9466МарейкоЮ. Е.MareikaYu. E.

Марейко Юлия Евгеньевна – врач-гематолог

ул. Фрунзенская, 43, 223053, д. Боровляны, Минский р-н

Yulia E. Mareika – Hematologist

43, Frunzenskaya Str., 223053, v. Borovliany, Minsk region 

mue@inbox.ruhttps://orcid.org/0000-0003-4814-804XМинаковскаяН. В.MinakovskayaN. V.

Минаковская Нина Вячеславовна – канд. мед. наук, доцент, врач-гематолог, заведующий отделением

ул. Фрунзенская, 43, 223053, д. Боровляны, Минский р-н

Nina V. Minakovskaya – Ph. D. (Med.), Associate Professor, Hematologist, Head of the Department

43, Frunzenskaya Str., 223053, v. Borovliany, Minsk region 

minakovskaya@tut.byhttps://orcid.org/0000-0003-0143-1921АлейниковаО. В.AleinikovaO. V.

Алейникова Ольга Витальевна – член-корреспондент, д-р мед. наук, профессор, гл. науч. сотрудник

ул. Фрунзенская, 43, 223053, д. Боровляны, Минский р-н

Olga V. Aleinikova – Corresponding Member, D. Sc. (Med.), Professor, Chief Researcher

43, Frunzenskaya Str., 223053, v. Borovliany, Minsk region 

aleinikova2004@mail.ruРеспубликанский научно-практический центр детской онкологии, гематологии и иммунологииBelarusian Research Center for Pediatric Oncology, Hematology and Immunology202106092021183375384Copyright © Прудников Д.В., Кирсанова Н.П., Марейко Ю.Е., Минаковская Н.В., Алейникова О.В., 20212021Прудников Д.В., Кирсанова Н.П., Марейко Ю.Е., Минаковская Н.В., Алейникова О.В.Prudnikau D.V., Kirsanava N.P., Mareika Y.E., Minakovskaya N.V., Aleinikova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/788

Известно, что после аллогенной трансплантации гемопоэтических клеток (алло-ТГСК) от HLAидентичного сиблинга или неродственного донора у 20‒25 % пациентов с острыми лейкозами наблюдается рецидив основного заболевания.Цель исследования – проанализировать влияние различных факторов на частоту возникновения рецидивов после алло-ТГСК у пациентов с острым лимфобластным лейкозом.Изучено влияние таких факторов, как пол и возраст донора на момент трансплантации, пол и возраст реципиента на момент трансплантации, вид и количество предшествующих ТГСК рецидивов, вид кондиционирования, тип трансплантации, источник стволовых клеток, параметры трансплантата, наличие или отсутствие острой (оРТПХ) или хронической (хрРТПХ) реакции трансплантат против хозяина, наличие KIR-аллореактивности естественных киллеров пары донор/реципиент.Установлено, что возраст пациентов менее 4 лет на момент трансплантации (p = 0,0042), время возникновения рецидива (очень ранний и ранний рецидив) (p = 0,0047), отсутствие оРТПХ (p = 0,0183) или хрРТПХ (p = 0,0384) являются факторами, ассоциированными с риском развития рецидива после алло-ТГСК.

More than 20–25 % of patients with acute leukemia underwent transplantation of HSC from HLA-identical sibling or unrelated donor had relapse.Therefore, the purpose of this study was to evaluate the influence of different factors on the risk of post-transplantation relapse in children and teenagers with acute lymphoblastic leukemia (ALL).The gender, the age of a donor at the time of transplantation; the gender, the age of a recipient at the time of transplantation; the type, the number of relapses of previous HSCTs; the type of conditioning; the type of transplantation; the source of stem cells; transplant parameters; the acute (aGVHD) and chronic (cGVHD) graft-versus-host disease or its absence; the KIRalloreactivity of donor NK cells were estimated as risk factors for the disease relapse in our study.We established that the recipient’s age of less than 4 years at the time of transplantation (p = 0.0042); the time of relapse (very early and early) (p = 0.0047); the absence of aGVHD (p = 0.0183) or cGVHD (p = 0.0384) have been the important factors for the disease relapse of patients with ALL after allogeneic HSC transplantation.

острые лейкозыфакторы рискарецидивыдетиострая РТПХхроническая РТПХacute leukemiarisk factorsrelapseschildrenacute GVHDchronic GVHDReferencesHaematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation / M. Miano [et al.] // Bone Marrow Transplant. ‒ 2007. ‒ Vol. 39, N 2. ‒ P. 89‒99. https://doi.org/10.1038/sj.bmt.1705550Miano M., Labopin M., Hartmann O., Angelucci E., Cornish J., Gluckman E. [et al.]. Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, vol. 39, no. 2, pp. 89‒99. https://doi.org/10.1038/sj.bmt.1705550Stem-Cell Transplantation in Children with Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors with Matched Unrelated Donors ‒ The ALL-SCT-BFM-2003 Trial / С. Peters [et al.] // J. Clin. Oncol. ‒ 2015. ‒ Vol. 33, N 11. ‒ P. 1265‒1273. https://doi.org/10.1200/JCO.2014.58.9747Peters C., Schrappe M., von Stackelberg A., Schrauder A., Bader P., Ebell W. [et al.]. Stem-Cell Transplantation in Children with Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors with Matched Unrelated Donors ‒ The ALL-SCT-BFM-2003 Trial. Journal of Clinical Oncology, 2015, vol. 33, no. 11, pp. 1265‒1273. https://doi.org/10.1200/JCO.2014.58.9747Pui, C-H. Acute lymphoblastic leukemia / C. H. Pui, W. E. Evans // N. Engl. J. Med. – 1998. – Vol. 339, N 9. ‒ P. 605–615. https://doi.org/10.1056/NEJM199808273390907Pui C-H., Evans W. E. Acute lymphoblastic leukemia. New England Journal of Medicine, 1998, vol. 339, no. 9, pp. 605–615. https://doi.org/10.1056/NEJM199808273390907NCI first international workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic cell transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies / E. P. Alyea [et al.] // Biol. Blood Marrow Transplant. – 2010. – Vol. 16, N 8. ‒ P. 1037–1069. https://doi.org/10.1016/j.bbmt.2010.04.004Pavletic S. Z., Kumar S., Mohty M., de Lima M., Foran J. M., Pasquini M., Zhang M. J., Giralt S., Bishop M. R., Weisdorf D. NCI first international workshop on the biology, prevention and treatment of relapse after allogeneic hematopoietic cell transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. Biology of Blood and Marrow Transplantation, 2010, vol. 16, no. 8, pp. 1037–1069. https://doi.org/10.1016/j.bbmt.2010.04.004Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts / S. Chiaretti [et al.] // Haematologica. – 2013. – Vol. 98, N 11. ‒ P. 1702–1710. https://doi.org/10.3324/haematol.2012.080432Chiaretti S., Vitale A., Cazzaniga G., Orlando S. M., Silvestri D., Fazi P. [et al.]. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica, 2013, vol. 98, no. 11, pp. 1702‒1710. https://doi.org/10.3324/haematol.2012.080432Prognostic index for relapsed acute leukemia after allogeneic stem cell transplant / K. Matsumoto [et al.] // Leuk. Lymphoma. – 2014. – Vol. 55, N 12. ‒ P. 2808–2812. https://doi.org/10.3109/10428194.2014.896004Matsumoto K., Yamamoto W., Ogusa E., Ishigatsubo Y., Kanamori H. Prognostic index for relapsed acute leukemia after allogeneic stem cell transplant. Leukemia and Lymphoma, 2014, vol. 55, no. 12, pp. 2808–2812. https://doi.org/10.3109/10428194.2014.896004Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia–rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation / J. Liu [et al.] // Biol. Blood Marrow Transplant. – 2014. – Vol. 20, N 7. ‒ P. 929–936. https://doi.org/10.1016/j.bbmt.2014.03.008Liu J., Wang Y., Xu L. P., Liu D. H., Qin Y. Z., Chang Y. J., Liu K. Y., Huang X. J. Monitoring mixed lineage leukemia expression may help identify patients with mixed lineage leukemia–rearranged acute leukemia who are at high risk of relapse after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2014, vol. 20, no. 7, pp. 929–936. https://doi.org/10.1016/j.bbmt.2014.03.008Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research / M. Eapen [et al.] // Blood. – 2006. – Vol. 107, N 12. ‒ P. 4961–4967. https://doi.org/10.1182/blood-2005-12-4942Eapen M., Raetz E., Zhang M. J., Muehlenbein C., Devidas M., Abshire T. [et al.]. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood, 2006, vol. 107, no. 12, pp. 4961–4967. https://doi.org/10.1182/blood-2005-12-4942Improvement of the outcome of relapsed or refractory acute lymphoblastic leukemia in children using a risk-based treatment strategy / F. Ceppi [et al.] // PLoS ONE. – 2016. – Vol. 11, N 9. – P. e0160310. https://doi.org/10.1371/journal.pone.0160310Ceppi F., Duval M., Leclerc J. M., Laverdiere C., Delva Y. L., Cellot S., Teira P., Bittencourt H. Improvement of the outcome of relapsed or refractory acute lymphoblastic leukemia in children using a risk-based treatment strategy. PLoS ONE, 2016, vol. 11, no. 9, p. e0160310. https://doi.org/10.1371/journal.pone.0160310Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome / M. B. Tomblyn [et al.] // J. Clin. Oncol. – 2009. – Vol. 27, N 22. ‒ P. 3634–3641. https://doi.org/10.1200/JCO.2008.20.2960Tomblyn M. B., Arora M., Baker K. S., Blazar B. R., Brunstein C. G., Burns L. J. [et al.]. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. Journal of Clinical Oncology, 2009, vol. 27, no. 22, pp. 3634–3641. https://doi.org/10.1200/JCO.2008.20.2960A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission / D. I. Marks [et al.] // Biol. Blood Marrow Transplant. – 2006. – Vol. 12, N 4. ‒ P. 438–453. https://doi.org/10.1016/j.bbmt.2005.12.029Marks D. I., Forman S. J., Blume K. G., Pérez W. S., Weisdorf D. J., Keating A. [et al.]. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biology of Blood and Marrow Transplantation, 2006, vol. 12, no. 4, pp. 438–453. https://doi.org/10.1016/j.bbmt.2005.12.029Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience / A. M. Willasch [et al.] // Bone Marrow Transplant. – 2017. – Vol. 52, N 2. ‒ P. 201–208. https://doi.org/10.1038/bmt.2016.224Willasch A. M., Salzmann-Manrique E., Krenn T., Duerken M., Faber J., Opper J. [et al.]. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience. Bone Marrow Transplantation, 2017, vol. 52, no. 2, pp. 201–208. https://doi.org/10.1038/bmt.2016.224Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention / F. Ceppi [et al.] // Expert Rev. Hematol. – 2015. – Vol. 8, N 1. ‒ P. 57‒70. https://doi.org/10.1586/17474086.2015.978281Ceppi F., Cazzaniga G., Colombini A., Biondi A., Conter V. Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention. Expert Review of Hematology, 2015, vol. 8, no. 1, pp. 57–70. https://doi.org/10.1586/17474086.2015.978281Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse / J. C. Beck [et al.] // Bone Marrow Transplant. – 2011. – Vol. 46, N 7. ‒ P. 950–955. https://doi.org/10.1038/bmt.2010.217Beck J. C., Cao Q., Trotz B., Smith A. R., Weigel B. J., Verneris M. R., Burke M. J. Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse. Bone Marrow Transplantation, 2011, vol. 46, no. 7, pp. 950–955. https://doi.org/10.1038/bmt.2010.217New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL / M. A. Pulsipher [et al.] // Bone Marrow Transplant. – 2014. – Vol. 49, N 10. ‒ P. 1259‒1265. https://doi.org/10.1038/bmt.2014.114Pulsipher M. A., Wayne A. S., Schultz K. R. New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL. Bone Marrow Transplantation, 2014, vol. 49, no. 10, pp. 1259‒1265. https://doi.org/10.1038/bmt.2014.114The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors / M. Remberger [et al.] // Bone Marrow Transplant. – 2002. – Vol. 30, N 7. ‒ P. 761–768. https://doi.org/10.1038/sj.bmt.1703735Remberger M., Mattsson J., Hentschke P., Aschan J., Barkholt L., Svennilson J., Ljungman P., Ringdén O. The graftversus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. Bone Marrow Transplantation, 2002, vol. 30, no. 7, pp. 761–768. https://doi.org/10.1038/sj.bmt.1703735Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial / F. Locatelli [et al.] // Blood. ‒ 2000. ‒ Vol. 95, N 5. ‒ P. 1572‒1579. https://doi.org/10.1182/blood.v95.5.1572.005k12_1572_1579Locatelli F., Zecca M., Rondelli R., Bonetti F., Dini G., Prete A. [et al.]. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood, 2000, vol. 95, no. 5, pp. 1572‒1579. https://doi.org/10.1182/blood.v95.5.1572.005k12_1572_1579Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival / A. Gustafsson Jernberg [et al.] // Bone Marrow Transplant. ‒ 2003. ‒ Vol. 31 (3). ‒ P. 175‒181. https://doi.org/10.1038/sj.bmt.1703808Gustafsson Jernberg A., Remberger M., Ringd’en O., Winiarski J. Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival. Bone Marrow Transplantation, 2003, vol. 31 (3), pp. 175‒181. https://doi.org/10.1038/sj.bmt.1703808Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: Higher CD34+ cell doses are associated with decreased relapse rates / R. Nakamura [et al.] // Biol. Blood Marrow Transplant. – 2008. – Vol. 14, N 4. ‒ P. 449–457. https://doi.org/10.1016/j.bbmt.2008.02.005Nakamura R., Auayporn N., Smith D. D., Palmer J., Sun J. Y., Schriber J. [et al.]. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: Higher CD34+ cell doses are associated with decreased relapse rates. Biology of Blood and Marrow Transplantation, 2008, vol. 14, no. 4, pp. 449–457. https://doi.org/10.1016/j.bbmt.2008.02.005Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose / M. A. Pulsipher [et al.] // Blood. – 2009. – Vol. 114, N 3. ‒ P. 2606–2616. https://doi.org/10.1182/blood-2009-03-208355Pulsipher M. A., Chitphakdithai P., Logan B. R., Leitman S. F., Anderlini P., Klein J. P., Horowitz M. M., Miller J. P., King R. J., Confer D. L. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood, 2009, vol. 114, no. 3, pp. 2606–2616. https://doi.org/10.1182/blood-2009-03-208355Higher CD34+ and CD3+ cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children / K. Kałwak [et al.] // Biol. Blood Marrow Transplant. – 2010. – Vol. 16, N 10. ‒ P. 1388–1401. https://doi.org/10.1016/j.bbmt.2010.04.001Kałwak K., Porwolik J., Mielcarek M., Gorczyńska E., Owoc-Lempach J., Ussowicz M. [et al.]. Higher CD34+ and CD3+ cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children. Biology of Blood and Marrow Transplantation, 2010, vol. 16, no. 10, pp. 1388–1401. https://doi.org/10.1016/j.bbmt.2010.04.001Risk factors and timing of relapse after allogeneic transplantation in Pediatric ALL: for whom and when should interventions be tested? / M. A. Pulsipher [et al.] // Bone Marrow Transplant. – 2015. – Vol. 50, N 9. ‒ P. 1173–1179. https://doi.org/10.1038/bmt.2015.103Pulsipher M. A., Langholz B., Wall D. A., Schultz K. R., Bunin N., Carroll W. [et al.]. Risk factors and timing of relapse after allogeneic transplantation in Pediatric ALL: for whom and when should interventions be tested? Bone Marrow Transplantation, 2015, vol. 50, no. 9, pp. 1173–1179. https://doi.org/10.1038/bmt.2015.103Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group / P. Bader [et al.] // J. Clin. Oncol. – 2009. – Vol. 27, N 3. ‒ P. 377–384. https://doi.org/10.1200/JCO.2008.17.6065Bader P., Kreyenberg H., Henze G. H., Eckert C., Reising M., Willasch A. [et al.]. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of Clinical Oncology, 2009, vol. 27, no. 3, pp. 377–384. https://doi.org/10.1200/JCO.2008.17.6065Minimal residual disease and childhood leukemia: standard of care recommendations from the Pediatric Oncology Group of Ontario MRD Working Group / U. H. Athale [et al.] // Pediatr. Blood Cancer. – 2016. – Vol. 63, N 6. ‒ P. 973–982. https://doi.org/10.1002/pbc.25939Athale U. H., Gibson P. J., Bradley N. M., Malkin D. M., Hitzler J. Minimal residual disease and childhood leukemia: standard of care recommendations from the Pediatric Oncology Group of Ontario MRD Working Group. Pediatric Blood and Cancer, 2016, vol. 63, no. 6, pp. 973–982. https://doi.org/10.1002/pbc.25939Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? ‒ A multicenter EBMT-PDWP study. A. Willasch [et al.] // Bone Marrow Transplant. ‒ 2020. ‒ Vol. 55, N 8. ‒ P. 1540–1551. https://doi.org/10.1038/s41409-020-0854-0Willasch A. M., Peters C., Sedláček P., Dalle J. H., Kitra-Roussou V., Yesilipek A. [et al.]. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy? ‒ A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 2020, vol. 55, no. 8, pp. 1540–1551. https://doi.org/10.1038/s41409-020-0854-0Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters / D. Bresters [et al.] // Bone Marrow Transplant. ‒ 2016. ‒ Vol. 51, N 11. ‒ P. 1482–1489. https://doi.org/10.1038/bmt.2016.139Bresters D., Lawitschka A., Cugno C., Pötschger U., Dalissier A., Michel G. [et al.]. Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. Bone Marrow Transplantation, 2016, vol. 51, no. 11, pp. 1482–1489. https://doi.org/10.1038/bmt.2016.139State-of the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29‒30 September 2015 / J.-H. Dalle [et al.] // Bone Marrow Transplant. ‒ 2017. ‒ Vol. 52, N 7. ‒ P. 1029–1035. https://doi.org/10.1038/bmt.2017.21Dalle J.-H., Lucchini G., Balduzzi A., Ifversen M., Jahnukainen K., Macklon K. T. [et al.]. State-of the-art fertility preservation in children and adolescents undergoing haematopoietic stem cell transplantation: a report on the expert meeting of the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplantation (EBMT) in Baden, Austria, 29‒30 September 2015. Bone Marrow Transplantation, 2017, vol. 52, no. 7, pp. 1029–1035. https://doi.org/10.1038/bmt.2017.21Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children / M. M. Pfeiffer [et al.] // Haematologica. ‒ 2010. ‒ Vol. 95, N 8. ‒ P. 1381‒1388. https://doi.org/10.3324/haematol.2009.021121Pfeiffer M. M., Feuchtinger T., Teltschik H. M., Schumm M., Müller I., Handgretinger R., Lang P. Reconstitution of natural killer cell receptors influences natural killer activity and relapse rate after haploidentical transplantation of T- and B-cell depleted grafts in children. Haematologica, 2010, vol. 95, no. 8, pp. 1381‒1388. https://doi.org/10.3324/haematol.2009.021121The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry / S. S. Farag [et al.] // Biol. Blood Marrow Transplant. ‒ 2006. ‒ Vol. 12, N 8. ‒ P. 876–884. https://doi.org/10.1016/j.bbmt.2006.05.007Farag S. S., Bacigalupo A., Eapen M., Hurley C., Dupont B., Caligiuri M. A. [et al.]. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biology of Blood and Marrow Transplantation, 2006, vol. 12, no. 8, pp. 876–884. https://doi.org/10.1016/j.bbmt.2006.05.007

The authors declare that there are no conflicts of interest present.